Literature DB >> 29921731

Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment.

Takuya Kato1, Kazuhiro Noma2, Toshiaki Ohara1,3, Hajime Kashima1, Yuki Katsura1, Hiroaki Sato1, Satoshi Komoto1, Ryoichi Katsube1, Takayuki Ninomiya1, Hiroshi Tazawa1,4, Yasuhiro Shirakawa1, Toshiyoshi Fujiwara1.   

Abstract

Purpose: Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a central role in tumor progression. We investigated whether CAFs can regulate tumor-infiltrating lymphocytes (TILs) and their role in tumor immunosuppression.Experimental Design: A total of 140 cases of esophageal cancer were analyzed for CAFs and CD8+ or forkhead box protein 3 (FoxP3+) TILs by IHC. We analyzed cytokines using murine or human fibroblasts and cancer cells. Murine-derived fibroblasts and cancer cells were also inoculated into BALB/c or BALB/c-nu/nu mice and the tumors treated with recombinant IL6 or anti-IL6 antibody.
Results: CD8+ TILs and CAFs were negatively correlated in intratumoral tissues (P < 0.001), whereas FoxP3+ TILs were positively correlated (P < 0.001) in esophageal cancers. Cocultured Colon26 cancer cells and fibroblasts resulted in accelerated tumor growth in BALB/c mice, along with decreased CD8+ and increased FoxP3+ TILs, compared with cancer cells alone. In vitro, IL6 was highly secreted in both murine and human cancer cell/fibroblast cocultures. IL6 significantly increased Colon26 tumor growth in immune-competent BALB/c (P < 0.001) with fewer CD8+ TILs than untreated tumors (P < 0.001), whereas no difference in BALB/c-nu/nu mice. In contrast, FoxP3+ TILs increased in IL6-treated tumors (P < 0.001). IL6 antibody blockade of tumors cocultured with fibroblasts resulted not only in regression of tumor growth but also in the accumulation of CD8+ TILs in intratumoral tissues.Conclusions: CAFs regulate immunosuppressive TIL populations in the TME via IL6. IL6 blockade, or targeting CAFs, may improve preexisting tumor immunity and enhance the efficacy of conventional immunotherapies. Clin Cancer Res; 24(19); 4820-33. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID: 29921731     DOI: 10.1158/1078-0432.CCR-18-0205

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  81 in total

1.  The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma.

Authors:  Hao Chen; Meng Yang; Qinghua Wang; Fengju Song; Xiangchun Li; Kexin Chen
Journal:  Oncoimmunology       Date:  2019-05-10       Impact factor: 8.110

Review 2.  The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors:  Miles Piper; Adam C Mueller; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-05-04       Impact factor: 4.784

3.  Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma.

Authors:  Shinichiro Watanabe; Kazuhiro Noma; Toshiaki Ohara; Hajime Kashima; Hiroaki Sato; Takuya Kato; Shinichi Urano; Ryoichi Katsube; Yuuri Hashimoto; Hiroshi Tazawa; Shunsuke Kagawa; Yasuhiro Shirakawa; Hisataka Kobayashi; Toshiyoshi Fujiwara
Journal:  Cancer Biol Ther       Date:  2019-06-11       Impact factor: 4.742

4.  CCL5 production by fibroblasts through a local renin-angiotensin system in malignant melanoma affects tumor immune responses.

Authors:  Kenta Nakamura; Yukiko Kiniwa; Ryuhei Okuyama
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-26       Impact factor: 4.553

Review 5.  Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation.

Authors:  Shabnam Shalapour; Michael Karin
Journal:  Immunity       Date:  2019-07-16       Impact factor: 31.745

6.  Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.

Authors:  Qiang Wen; Zhe Yang; Jian Zhu; Qingtao Qiu; Honghai Dai; Alei Feng; Ligang Xing
Journal:  Onco Targets Ther       Date:  2020-11-20       Impact factor: 4.147

7.  A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.

Authors:  Kiyohiro Ando; Kazuyuki Hamada; Midori Shida; Ryotaro Ohkuma; Yutaro Kubota; Atsushi Horiike; Hiroto Matsui; Tomoyuki Ishiguro; Yuya Hirasawa; Hirotsugu Ariizumi; Makoto Watanabe; Rie Onoue; Junji Tsurutani; Kiyoshi Yoshimura; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada
Journal:  Cancer Immunol Immunother       Date:  2020-08-05       Impact factor: 6.968

Review 8.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

Review 9.  The Immune Microenvironment and Cancer Metastasis.

Authors:  Asmaa El-Kenawi; Kay Hänggi; Brian Ruffell
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

10.  The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval.

Authors:  Kimberly R Jordan; Matthew J Sikora; Jill E Slansky; Angela Minic; Jennifer K Richer; Marisa R Moroney; Junxiao Hu; Rebecca J Wolsky; Zachary L Watson; Tomomi M Yamamoto; James C Costello; Aaron Clauset; Kian Behbakht; T Rajendra Kumar; Benjamin G Bitler
Journal:  Clin Cancer Res       Date:  2020-09-14       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.